143 related articles for article (PubMed ID: 9838547)
21. Experience with neoral cyclosporine through the oral route in liver transplantation.
Bilbao I; Lazaro JL; Pou L; Charco R; Hildalgo E; Murio E; Margarit C
Transplant Proc; 1998 Jun; 30(4):1432-4. PubMed ID: 9636580
[No Abstract] [Full Text] [Related]
22. Conversion from cyclosporine to tacrolimus in kidney, kidney/pancreas, and pancreas alone transplant recipients: the Memphis experience.
Alloway RR; Russell WC; Gaber LW; Amiri MH; Vera SR; Gaber AO
Transplant Proc; 1996 Apr; 28(2):995-7. PubMed ID: 8623494
[No Abstract] [Full Text] [Related]
23. Mycophenolate mofetil eliminates the rationale for antilymphocyte induction therapy in nonhaploidentical living-donor kidney transplants.
Shaffer D; Madras PN; Conway P; Davis C; Simpson MA; Monaco AP
Transplant Proc; 1997; 29(1-2):342-3. PubMed ID: 9123031
[No Abstract] [Full Text] [Related]
24. The early impact of mycophenolate mofetil in combination with steroids and cyclosporine Neoral after renal transplantation: a six-month analysis.
Cubas A; Herrero JC; Morales E; Carreño A; Dominguez-Gil B; Cirujeda A; Praga M; Ortuño T; Hernandez E; Delgado M; Andres A; Morales JM
Transplant Proc; 1999 Sep; 31(6):2265-6. PubMed ID: 10500570
[No Abstract] [Full Text] [Related]
25. A meta-analysis to assess the safety and tolerability of two formulations of cyclosporine: Sandimmune and Neoral.
Shah MB; Martin JE; Schroeder TJ; First MR
Transplant Proc; 1998 Dec; 30(8):4048-53. PubMed ID: 9865291
[No Abstract] [Full Text] [Related]
26. Excellent long-term survival of low-risk, first renal allografts using cyclosporine/azathioprine double therapy.
Faull RJ; Bannister KM; Russ GR; Mathew TH; Clarkson AR
Transplant Proc; 1999; 31(1-2):1155-6. PubMed ID: 10083516
[No Abstract] [Full Text] [Related]
27. Neoral versus Sandimmune in kidney transplantation.
Tisone G; Orlando G; Mercadante E; Vennarecci G; Pisani F; Buonomo O; Negrini S; Casciani CU
Transplant Proc; 1998 Aug; 30(5):1749-50. PubMed ID: 9723265
[No Abstract] [Full Text] [Related]
28. Case studies: conversion from Sandimmune to Neoral in stable renal allograft recipients.
Roth D; Miller J
Transplant Proc; 1996 Aug; 28(4):2219-20; discussion 2218. PubMed ID: 8769204
[No Abstract] [Full Text] [Related]
29. Clinical outcomes during the first three months posttransplant in renal allograft recipients managed by C2 monitoring of cyclosporine microemulsion.
Thervet E; Pfeffer P; Scolari MP; Toselli L; Pallardó LM; Chadban S; Pilmore H; Connolly J; Buchler M; Schena FP; Carreño CA; Dandavino R; Cole E
Transplantation; 2003 Sep; 76(6):903-8. PubMed ID: 14508352
[TBL] [Abstract][Full Text] [Related]
30. Kidney transplantation in pediatric population.
Mota C; Henriques C; Sarmento M; Pereira E; Xavier E; Pereira M
Transplant Proc; 1994 Oct; 26(5):2768-70. PubMed ID: 7940872
[No Abstract] [Full Text] [Related]
31. Cyclosporine therapy in pancreas transplantation.
Davidson I; Lu C; Melone D; Risser R
Transplant Proc; 1996 Aug; 28(4):2134-5. PubMed ID: 8769179
[No Abstract] [Full Text] [Related]
32. Assessment of two strategies of neoral administration, early versus delayed, on renal function and efficacy in de novo renal transplant patients receiving myfortic, steroids, and anti-IL2R antibodies: 12-month results of a randomized, multicentre, open, prospective controlled study.
Mourad G; Rostaing L; Legendre Ch;
Transplant Proc; 2005 Mar; 37(2):920-2. PubMed ID: 15848575
[TBL] [Abstract][Full Text] [Related]
33. Comparison of microemulsion and conventional formulations of cyclosporine A in preventing acute rejection in de novo kidney transplant patients. The U.K. Neoral Renal Study Group.
Pollard SG; Lear PA; Ready AR; Moore RH; Johnson RW
Transplantation; 1999 Nov; 68(9):1325-31. PubMed ID: 10573071
[TBL] [Abstract][Full Text] [Related]
34. Donor-specific transfusion under the new cyclosporine A formulation Consupren versus azathioprine, Imuran.
Kamel G; Stephan A; Masri MA; Barbari A; Kelany H; Younan F; Karam A
Transplant Proc; 1997 Nov; 29(7):2960-1. PubMed ID: 9365629
[No Abstract] [Full Text] [Related]
35. Case study: conversion of a liver transplant patient from cyclosporine Sandimmune to Neoral.
Levy GA
Transplant Proc; 1996 Aug; 28(4):2252-3. PubMed ID: 8769216
[No Abstract] [Full Text] [Related]
36. Withdrawal versus continuous cyclosporine therapy in kidney transplant recipients of one-haplotype-matched donors.
Chew-Wong A; Alberú J; Abasta-Jiménez M; Alvarez-Sandoval E; Gabilondo-Navarro F; Correa-Rotter R
Transplant Proc; 1999; 31(1-2):1106-9. PubMed ID: 10083494
[No Abstract] [Full Text] [Related]
37. Cyclosporin Neoral and long-term survival of renal grafts.
Shaheen FA; Sheikh IA; al-Khader A
Transplant Proc; 1998 Nov; 30(7):3549. PubMed ID: 9838553
[No Abstract] [Full Text] [Related]
38. Immunological and nonimmunological risk factors with tacrolimus and Neoral in renal transplant recipients: an interim report.
Jurewicz WA
Transplant Proc; 1999 Nov; 31(7A):64S-66S. PubMed ID: 10576048
[No Abstract] [Full Text] [Related]
39. Comparison between three different antilymphocyte induction protocols in renal transplant recipients with delayed graft function.
Sumrani N; Hong JH; DiBenedetto A; Clayton R; Miles AM; Markell MS; Distant DA; Fleishhacker J; Sommer BG
Transplant Proc; 1996 Feb; 28(1):400-1. PubMed ID: 8644289
[No Abstract] [Full Text] [Related]
40. FK 506 in kidney transplantation: results of the U.S.A. randomized comparative phase III study. The FK 506 Kidney Transplant Study Group.
Miller J; Pirsch JD; Deierhoi M; Vincenti F; Filo RS
Transplant Proc; 1997; 29(1-2):304-5. PubMed ID: 9123008
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
